Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Shareholder Meeting (September 2023)
13 slides from Chimeric Therapeutics's shareholder meeting presentation, Sep 13, 2023
Slide 1: Bringing the Promise of Cell Therapy to Life
BRINGING THE PROMISE OF CELL For personal use only THERAPY TO LIFE Chimeric Therapeutics EGM September 13, 2023
Slide 2: Disclaimer
DISCLAIMER For personal use only Certain statements contained in this presentation, including, information or studies to be completed or provided prior to their without limitation, statements containing the words “believes,” approval of our products. “plans,” “expects,” “anticipates,” and words of s
Slide 3: Chimeric: A Foundation for Long Term Success
CHIMERIC: A FOUNDATION FOR LONG TERM SUCCESS 3 NOVEL PLATFORM TECHNOLOGIES For personal use only CHM 1101 CHM 2101 CHM 0201 (CLTX CAR T) (CDH17 CAR T) (CORE NK) 2020 2021 2022 First in class CLTX CAR T First in class CDH17 CAR T Best in class NK cell platform
Slide 4: Stages of Clinical Development in Oncology Drug Development
GOAL ONCOLOGY DRUG DEVELOPMENT STAGES OF CLINICAL DEVELOPMENT Phase 3 For personal use only Phase 2 3-5 years Phase 1B 2-4 years Phase 1A Preclinical 1-2 years In Vivo 1-2 years Preclinical In Vitro 1-2 years 2-4 years Animal ~10-20 ~15-30 ~100-200 ~300-600 Models Patients Patients Patients Patients
Slide 5: Chimeric Asset Development Goal
CHIMERIC ASSET DEVELOPMENT GOAL CREATING VALUE BY ADVANCING CLINICAL DEVELOPMENT Phase 3 For personal use only 3-5 years Phase 2 2-4 years Phase 1B Phase 1A 1-2 years Only if Required Preclinical 1-2 years CHM 1101 In Vivo Initiated Historically Preclinical In CHM 1101 Not 1-2 years CHM0201+Va
Slide 6: Today's Biotech Market: Challenges in Reflecting Value
TODAY’S BIOTECH MARKET CHALLENGES IN REFLECTING VALUE For personal use only 93% Biotech IPO market decrease since 20211 CHM Market Information 20%+ of the Nasdaq Biotech Index’s companies have market valuations for less than cash on hand2. 29% Of American and European biotech companies have cash res
Slide 7: Chimeric Focus
CHIMERIC FOCUS WHAT ARE WE DOING TO ADDRESS THE CHALLENGES For personal use only PROGRAM PRIORITIZATION CASH PRESERVATION BUSINESS DEVELOPMENT
Slide 8: CHM 1101 in Brain Cancer
CHM 1101 in BRAIN CANCER PHASE 1A COMPLETE, NEAR-TERM CLINICAL MILESTONE For personal use only 2021 AUG 23 NOV 23 PHASE 1A CLINICAL TRIAL IN RECURRENT PHASE 1A COMPLETION PHASE 1A PRELIMINARY GLIOBLASTOMA OF DOSE ESCALATION DOSE ESCALATION DATA JUN 23 2024 PHASE 1B PHASE 1B DOSE CONFIRMATION DOSE EX
Slide 9: CHM 0201: Advancing Novel Phase 1B Clinical Combinations
CHM 0201 ADVANCING NOVEL PHASE 1B CLINICAL COMBINATIONS For personal use only CHM 0201 CHM 0201 + VACTO CHM 0201 + AZA/VEN Phase 1A Phase 1B Phase 1B COMPLETE TO ENROLLMENT ONGOING ENROLLMENT ENROLLMENT LATE 2023 Established Safety Initiated January 2023 FDA IND Clearance Complete Response in Acute
Slide 10: CHM 2101: Advancing Towards Clinic
CHM 2101 ADVANCING TOWARDS CLINIC For personal use only PRECLINICAL PRECLINICAL VECTOR FDA TECHNICAL FDA IN VITRO IN VIVO MANUFACTURING PRE IND OPERATIONS IND STUDIES STUDIES & RELEASE MEETING READINESS CLEARANCE
Slide 11: Chimeric Therapeutics Positioned for Success
CHIMERIC THERAPEUTICS POSITIONED FOR SUCCESS For personal use only ADVANCING PROGRAM PRIORITIZATION BIOTECH MARKET CLINICAL ADVANCEMENT WITH CASH PRESERVATION OUTLOOK Clinical progress with near-term Focus on clinical programs and milestones cash preservation 2023 increase in M&A activity in cell th
Slide 12: Success in CAR T Cell Development
SUCCESS IN CAR T CELL DEVELOPMENT 7 YEARS CANCER FREE For personal use only
Slide 13: Contact Information
CONTACT INFORMATION For personal use only Jennifer Chow Chief Executive Officer and Managing Director Chimeric Therapeutics Ltd Cell: +1 908-723-8387 jchow@chimerictherapeutics.com Paul A. Hopper Executive Chairman Chimeric Therapeutics Ltd Cell: +61 406671515 paulhopper@lifescienceportfolio.com
Chimeric Therapeutics — Shareholder Meeting (September 2023) on 6ix